BASF and Biomillenia join forces in microbiome research to promote healthy skin

7 Oct 2019

Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

BASF and Biomillenia have signed a microbiome discovery agreement, which aims to identify novel dermocosmetic active ingredients involved in promoting skin health.

BASF and Biomillenia join forces in microbiome research to promote healthy skin

The French company Biomillenia will contribute its unique microbiome-on-a-chip technology that has the ability to grow specific microbes and maintain a higher diversity of living microbes than with standard microbiology methods. It will allow BASF to explore how active ingredients can modulate the presence and growth of the skin microbiota, and consequently affect its health. By bringing together interdisciplinary know-how from within the company as well as from external partners, BASF constantly expands its activities dedicated to developing solutions acting on or through the skin microbiota. “The skin hosts a huge and varied microbiota and as such plays an important role in skin health. Biomillenia’s ability to rapidly identify novel microbes and screen for active ingredients involved in promoting healthy skin will enable new research possibilities and market opportunities for BASF,” said David Hérault, R&D Global Director of BASF Beauty Care Solutions. “The microbiome is a vast natural pool of mostly undiscovered microbes that can be leveraged across several industries, including consumer health, agriculture, animal health and food. We are supporting companies in these sectors by providing access to our technology platform to culture and perform functional analysis of microbes in low volume droplets using proprietary lab-on-a-chip technology. In addition, our customers can gain access to our microbial culture collection and state of the art microbe isolation and sequencing technologies,” said Dirk Loeffert, Ph.D., CEO of Biomillenia.

Read More

Related news

Funding to accelerate delivery of Univercells' vaccine portfolio

Funding to accelerate delivery of Univercells' vaccine portfolio

11 Oct 2019

European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

Read more 
Industrial-scale manufacture of therapeutic exosomes

Industrial-scale manufacture of therapeutic exosomes

10 Oct 2019

Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

Read more 
Arctoris secures funding to advance novel robotic drug discovery platform

Arctoris secures funding to advance novel robotic drug discovery platform

1 Oct 2019

Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,

Read more 
Data on lead ADC demonstrates effective tumour regression

Data on lead ADC demonstrates effective tumour regression

1 Oct 2019

IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer.

Read more 
Researchers develop less toxic anti-cancer drug

Researchers develop less toxic anti-cancer drug

24 Sep 2019

New drug works like a ‘magic bullet’ that is delivered directly to the mitochondria of cancer cells.

Read more 
EC approves its first plant-derived cannabis-based medicine

EC approves its first plant-derived cannabis-based medicine

24 Sep 2019

Epidyolex (cannabidiol) approved for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Read more 
Study demonstrates potential of blood test for early lung cancer detection

Study demonstrates potential of blood test for early lung cancer detection

16 Sep 2019

Ground-breaking trial demonstrates potential of blood test which harnesses the power of the immune system to reduce late detection of lung cancer.

Read more 
M2i Life Sciences completes a historic fundraising of 60 million Euros

M2i Life Sciences completes a historic fundraising of 60 million Euros

16 Sep 2019

To support its strong growth, M2i Life Sciences has concluded a capital increase of 60 million Euros with five leading investors (ADM Capital, Eurazeo Growth, Téthys Invest, Creadev and France 2i fund managed by RAISE Impact).

Read more 
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

10 Sep 2019

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Read more 
BioCity backs world's first Rx to OTC switch incubator

BioCity backs world's first Rx to OTC switch incubator

5 Sep 2019

Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.

Read more